The evidence for DIM includes moderate support for body fat reduction and prostate cancer biomarker modulation. However, while some studies show promise in breast cancer contexts, the overall research is still limited and requires further validation.
Breast densityHealthy BRCA carriers · Prospective clinical trialLow
DIM was well tolerated with no significant toxicity observed.
Breast cancer biomarker modulationPatients taking tamoxifen · RCTLow
Limited evidence of clinically relevant activity of DIM in breast cancer biomarker modulation.
Estrogen metabolismWomen taking tamoxifen · RCTModerate
BR-DIM increased the 2/16α-OHE1 ratio and serum SHBG compared to placebo.
Cervical intraepithelial neoplasia (CIN) improvementPatients with CIN 2 or 3 · RCTModerate
DIM showed a high rate of clinically significant improvement in CIN lesions.
Breast cancer biomarker modulationPatients taking tamoxifen · RCTLow
DIM showed potential in modulating breast cancer biomarkers, although further research is needed to confirm clinical benefits.
Body fat reductionPremenopausal women · RCTModerate
DIM supplementation favored benign estrogen metabolism pathways & was associated with decreased body fat.
Prostate cancer biomarkersPatients with prostate cancer undergoing prostatectomy · RCTModerate
BR-DIM was associated with modulation of prostate cancer biomarkers, suggesting potential therapeutic benefits.
Estrogen metabolismWomen taking tamoxifen · RCTModerate
BR-DIM increased the 2/16α-hydroxyestrone ratio & serum SHBG levels, indicating favorable changes in estrogen metabolism.
Forms & usage▾
Take 100-300 mg daily with food for best absorption.